In This Article:
NASDAQ:TELO
READ THE FULL TELO RESEARCH REPORT
Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”
Continuing a string of positive news, the company just released more preclinical results, this time revolving around Progeria research. Progeria, also known as Hutchinson-Gilford Progeria Syndrome, is a rare genetic condition that causes children to experience rapid aging. Fewer than 400 children worldwide are affected by this devastating disease, which leads to growth failure, joint stiffness, cardiovascular complications, and premature death, often in the early teens or twenties.
According to the company, at the molecular level, progeria is driven by the accumulation of progerin, an abnormal protein that disrupts the cell nucleus and impairs normal gene expression. This damage accelerates telomere shortening, leaving DNA vulnerable and contributing to widespread cellular dysfunction. Telomeres, the protective caps at the ends of chromosomes, naturally shorten with normal aging, but this process is dramatically accelerated in progeria, leading to premature cellular aging.
The release from the company details the study, which was conducted in nematodes with a mutation in the wrn-1 gene, which is equivalent to a gene in humans associated with Werner Syndrome (a form of Progeria). Compared to normal (wild-type) nematodes, those with wrn-1 depletion showed a significantly reduced mean and median lifespan. According to the company, utilizing advanced in vivo microfluidic technology, the study demonstrated lifespan restoration and normalization of accelerated aging effects in wrn-1-mutated nematodes treated with Telomir-1.
The results of the study according to management was that the treatment effectively restored longevity to levels not significantly different from normal animals. These effects included an extended healthy lifespan and the normalization of several physiological parameters, such as movement velocity and tail amplitude.
Following the study, Laurent Mouchiroud, CSO of Nagi Biosciences NA, which collaborated with Telomir on the study, noted, “The analysis confirms that Telomir-1 not only restores lifespan but also effectively counters the decline observed in untreated populations. These findings underscore Telomir-1’s potential to transform how we address age-related conditions by targeting their underlying cellular mechanisms.”